Literature DB >> 20127169

Bone health in a tertiary-care gastroenterology and hepatology population.

Millie D Long1, Michelle T Thiny, Robert S Sandler, Lisa M Gangarosa.   

Abstract

BACKGROUND: Glucocorticoid use is a major risk factor for osteoporosis. Overall rates of glucocorticoid use and bone health preventive measures in gastroenterology and hepatology populations are unknown. AIMS: We aimed to determine the rates of glucocorticoid use and bone health preventive measures, to evaluate an education-based quality improvement initiative on bone health and to assess improvement in health-care practices of providers in regard to bone health recommendations.
METHODS: A cross-sectional survey was offered to all patients visiting a tertiary care gastroenterology and hepatology clinic. A bone health education intervention was performed, followed by a repeat cross-sectional survey. Pearson's Chi-square test statistic was used to evaluate interval improvement in bone health recommendations with the intervention. Predictive multiple logistic regression modeling was used to determine factors that influenced bone health recommendations by providers.
RESULTS: A total of 552 patients and 725 patients completed the pre and post-intervention questionnaires, respectively. The prevalence of glucocorticoid use was 12.9%. Bone health recommendations to patients on glucocorticoids did not improve with the intervention (63.0% vs. 55.4%, p = 0.42). The strongest predictor of bone health recommendations was autoimmune hepatitis (OR 6.60 95%CI 3.13, 13.90), followed by inflammatory bowel disease (OR 6.06 95%CI 3.92, 9.38), liver disease (OR 3.70 95%CI 2.45, 5.59), current smoking (OR 3.31 95%CI 2.32, 4.73) and history of osteoporosis/osteopenia (OR 2.72 95%CI 1.83, 4.03).
CONCLUSIONS: In spite of risk factors for osteoporosis in patients with digestive diseases, health-care practices by providers in regard to bone health recommendations warrant further improvement.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20127169      PMCID: PMC2894281          DOI: 10.1007/s10620-010-1130-8

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  21 in total

1.  American Gastroenterological Association medical position statement: guidelines on osteoporosis in gastrointestinal diseases.

Authors: 
Journal:  Gastroenterology       Date:  2003-03       Impact factor: 22.682

2.  Multifaceted educational program increases prescribing of preventive medication for corticosteroid induced osteoporosis.

Authors:  Mark Naunton; Gregory M Peterson; Graeme Jones; Gillian M Griffin; Martin D Bleasel
Journal:  J Rheumatol       Date:  2004-03       Impact factor: 4.666

3.  Prevention of glucocorticoid osteoporosis: a consensus document of the Dutch Society for Rheumatology.

Authors:  P P Geusens; R N J de Nijs; W F Lems; R F J M Laan; A Struijs; T P van Staa; J W J Bijlsma
Journal:  Ann Rheum Dis       Date:  2004-03       Impact factor: 19.103

4.  Survey of gastroenterologists' awareness and implementation of AGA guidelines on osteoporosis in inflammatory bowel disease patients: are the guidelines being used and what are the barriers to their use?

Authors:  Julianne H Wagnon; David A Leiman; Gregory D Ayers; David A Schwartz
Journal:  Inflamm Bowel Dis       Date:  2009-07       Impact factor: 5.325

5.  American Gastroenterological Association medical position statement: osteoporosis in hepatic disorders.

Authors: 
Journal:  Gastroenterology       Date:  2003-09       Impact factor: 22.682

6.  Variations in glucocorticoid induced osteoporosis prevention in a managed care cohort.

Authors:  A Mudano; J Allison; J Hill; T Rothermel; K Saag
Journal:  J Rheumatol       Date:  2001-06       Impact factor: 4.666

7.  An evaluation of managing and educating patients on the risk of glucocorticoid-induced osteoporosis.

Authors:  Randy P McDonough; William R Doucette; Patty Kumbera; Donald G Klepser
Journal:  Value Health       Date:  2005 Jan-Feb       Impact factor: 5.725

Review 8.  Prevention and treatment of glucocorticoid-induced osteoporosis with active vitamin D3 analogues: a review with meta-analysis of randomized controlled trials including organ transplantation studies.

Authors:  R N J de Nijs; J W G Jacobs; A Algra; W F Lems; J W J Bijlsma
Journal:  Osteoporos Int       Date:  2004-05-07       Impact factor: 4.507

9.  Suggested guidelines for evaluation and treatment of glucocorticoid-induced osteoporosis for the Department of Veterans Affairs.

Authors:  Robert A Adler; Marc C Hochberg
Journal:  Arch Intern Med       Date:  2003-11-24

10.  The design of a valid and reliable questionnaire to measure osteoporosis knowledge in women: the Osteoporosis Knowledge Assessment Tool (OKAT).

Authors:  Tania M Winzenberg; Brian Oldenburg; Sue Frendin; Graeme Jones
Journal:  BMC Musculoskelet Disord       Date:  2003-07-24       Impact factor: 2.362

View more
  1 in total

Review 1.  Recent updates on the management of autoimmune hepatitis.

Authors:  Atsumasa Komori
Journal:  Clin Mol Hepatol       Date:  2020-12-10
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.